Analysis

Hurdles Ahead For AbbVie After $150M AndroGel Verdict

Law360, Chicago (August 3, 2017, 6:33 PM EDT) -- An Illinois federal jury may have cleared AbbVie of causing an AndroGel user's heart attack, but its award of $150 million in punitive damages against the drugmaker for misleading advertising saddles AbbVie with clear challenges in future trials in multidistrict litigation, attorneys say.

The monetary award in the July 24 verdict grabbed headlines, yet while circumstances around the damages may allow AbbVie to avoid a payout, experts say the jury's conclusion that the company should be punished for advertising AndroGel to treat drops in testosterone — ads AbbVie claims had U.S. Food and Drug Administration approval — will be hard for the company...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!